Abstract
e20085 Background: Activating mutations in BRAF gene are present in 40-60% of metastatic MEL patients (pts). VEM is an inhibitor of kinase domain in mutated BRAF. In previous trials VEM had been sh...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
